Questcor Pharmaceuticals CEO Unloads $2,486,400 in Stock (QCOR)
Questcor Pharmaceuticals (NASDAQ:QCOR) CEO Don Bailey unloaded 40,000 shares of the stock on the open market in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $62.16, for a total transaction of $2,486,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on QCOR shares. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. They now have a $66.40 price target on the stock. Separately, analysts at Ned Davis Research downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Monday, September 30th. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Questcor Pharmaceuticals in a research note to investors on Tuesday, September 17th. They set a “neutral” rating and a $71.00 price target on the stock. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $73.37.
Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 5.50% on Wednesday, hitting $66.731. The stock had a trading volume of 1,954,343 shares. Questcor Pharmaceuticals has a 52-week low of $21.53 and a 52-week high of $74.76. The stock’s 50-day moving average is $62.17 and its 200-day moving average is $48.50. The company has a market cap of $3.933 billion and a price-to-earnings ratio of 16.98.
Questcor Pharmaceuticals (NASDAQ:QCOR) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.16. The company had revenue of $184.60 million for the quarter, compared to the consensus estimate of $168.96 million. During the same quarter in the previous year, the company posted $0.65 earnings per share. The company’s revenue for the quarter was up 64.1% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $4.83 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, October 30th. Shareholders of record on Tuesday, October 22nd will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend is Friday, October 18th. This is a positive change from Questcor Pharmaceuticals’s previous quarterly dividend of $0.25.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.